BACKGROUND: Thyroid cancer incidence is increasing, potentially due to enhanced diagnostic practices. However, access to healthcare may be dependent on socioeconomic status (SES) and race/ethnicity. Consequently, certain segments of the population may experience thyroid cancer overdiagnosis as a result of greater access to and use of enhanced diagnostic technology. The current study examined trends by SES in thyroid cancer incidence at the census tract level from 1995 to 2008 for the population of Texas, as well as by racial/ethnic subgroup. METHODS: Joinpoint regressions were used to examine incidence trends over time by SES for the study population, and for the non-Hispanic white, non-Hispanic black, and Hispanic subgroups separately. Other race/ethnicities were not adequately represented for subgroup analyses. RESULTS: There were 22,390 incident thyroid cancer cases (65.0% white, 6.7% black, 24.3% Hispanic, 4.1% Asian/other races; 85.9% papillary histology). The low SES group experienced a steady increase in incidence since 1995 (6.7% per year, p<0.05), whereas incidence among the high SES group has increased at a rate of 8.6% per year since 1999 (p<0.05). The joinpoint projected incidence trends for the low and high SES groups were significantly different (p=0.047). Whites experienced a steady increase in incidence over time among both high and low SES groups (7.6% per year p<0.05), whereas blacks and Hispanics of higher SES had a much more pronounced increase in incidence over time relative to their lower SES counterparts (blacks=12.8% vs. 4.1%; Hispanics=11.2% vs. 8.3%, p<0.05). For blacks and Hispanics, joinpoint projected incidence trends for the low and high SES groups were significantly different from one another (p<0.001-0.004). CONCLUSIONS: These results identify groups experiencing the greatest problem of increasing thyroid cancer incidence, and raise concern that greater access to healthcare may be accompanied by thyroid cancer overdiagnosis. A dual focus on delineating and preventing disease-related causal factors and focusing clinical attention on avoiding overdiagnosis among certain populations (e.g., high SES) may be advisable to address thyroid cancer in Texas. Clinicians are encouraged to adhere to ATA/NCCN guidelines when choosing patients for thyroid ultrasound, selecting which nodules to examine, and deciding which patients should proceed to biopsy.
BACKGROUND:Thyroid cancer incidence is increasing, potentially due to enhanced diagnostic practices. However, access to healthcare may be dependent on socioeconomic status (SES) and race/ethnicity. Consequently, certain segments of the population may experience thyroid cancer overdiagnosis as a result of greater access to and use of enhanced diagnostic technology. The current study examined trends by SES in thyroid cancer incidence at the census tract level from 1995 to 2008 for the population of Texas, as well as by racial/ethnic subgroup. METHODS: Joinpoint regressions were used to examine incidence trends over time by SES for the study population, and for the non-Hispanic white, non-Hispanic black, and Hispanic subgroups separately. Other race/ethnicities were not adequately represented for subgroup analyses. RESULTS: There were 22,390 incident thyroid cancer cases (65.0% white, 6.7% black, 24.3% Hispanic, 4.1% Asian/other races; 85.9% papillary histology). The low SES group experienced a steady increase in incidence since 1995 (6.7% per year, p<0.05), whereas incidence among the high SES group has increased at a rate of 8.6% per year since 1999 (p<0.05). The joinpoint projected incidence trends for the low and high SES groups were significantly different (p=0.047). Whites experienced a steady increase in incidence over time among both high and low SES groups (7.6% per year p<0.05), whereas blacks and Hispanics of higher SES had a much more pronounced increase in incidence over time relative to their lower SES counterparts (blacks=12.8% vs. 4.1%; Hispanics=11.2% vs. 8.3%, p<0.05). For blacks and Hispanics, joinpoint projected incidence trends for the low and high SES groups were significantly different from one another (p<0.001-0.004). CONCLUSIONS: These results identify groups experiencing the greatest problem of increasing thyroid cancer incidence, and raise concern that greater access to healthcare may be accompanied by thyroid cancer overdiagnosis. A dual focus on delineating and preventing disease-related causal factors and focusing clinical attention on avoiding overdiagnosis among certain populations (e.g., high SES) may be advisable to address thyroid cancer in Texas. Clinicians are encouraged to adhere to ATA/NCCN guidelines when choosing patients for thyroid ultrasound, selecting which nodules to examine, and deciding which patients should proceed to biopsy.
Authors: Shawn D Larson; Lindsey N Jackson; Taylor S Riall; Tatsuo Uchida; Robert P Thomas; Suimin Qiu; B Mark Evers Journal: J Am Coll Surg Date: 2007-02-23 Impact factor: 6.113
Authors: Ian Mitchell; Edward H Livingston; Alice Y Chang; Shelby Holt; William H Snyder; Ildiko Lingvay; Fiemu E Nwariaku Journal: Surgery Date: 2007-12 Impact factor: 3.982
Authors: Nancy Krieger; Jarvis T Chen; Pamela D Waterman; David H Rehkopf; S V Subramanian Journal: Am J Public Health Date: 2003-10 Impact factor: 9.308
Authors: John P Hanley; Erin Jackson; Leslie A Morrissey; Donna M Rizzo; Brian L Sprague; Indra Neil Sarkar; Frances E Carr Journal: Thyroid Date: 2015-06-02 Impact factor: 6.568
Authors: Mariel S Bello; Raina D Pang; Karen L Cropsey; Michael J Zvolensky; Lorraine R Reitzel; Jimi Huh; Adam M Leventhal Journal: Nicotine Tob Res Date: 2015-10-18 Impact factor: 4.244
Authors: Claudia G Aguirre; Mariel S Bello; Nafeesa Andrabi; Raina D Pang; Peter S Hendricks; Ricky N Bluthenthal; Adam M Leventhal Journal: Behav Modif Date: 2015-10-05
Authors: Dana Hashim; Zeinab Farhat; Sylvan Wallenstein; Marta Manczuk; Randall F Holcombe; Lorna Thorpe; Maria J Schymura; Roberto G Lucchini; Paolo Boffetta Journal: Eur J Cancer Prev Date: 2016-07 Impact factor: 2.497
Authors: Hilary L Colbeth; Natalia Genere; Charles B Hall; Nadia Jaber; Juan P Brito; Omar M El Kawkgi; David G Goldfarb; Mayris P Webber; Theresa M Schwartz; David J Prezant; Rachel Zeig-Owens Journal: JAMA Intern Med Date: 2020-06-01 Impact factor: 21.873
Authors: Jonathan Zagzag; Michael K Malone; Melissa A Lopresti; Jennifer B Ogilvie; Kepal N Patel; Keith S Heller Journal: PLoS One Date: 2016-04-04 Impact factor: 3.240
Authors: David G Goldfarb; Hilary L Colbeth; Molly Skerker; Mayris P Webber; David J Prezant; Christopher R Dasaro; Andrew C Todd; Dana Kristjansson; Jiehui Li; Robert M Brackbill; Mark R Farfel; James E Cone; Janette Yung; Amy R Kahn; Baozhen Qiao; Maria J Schymura; Paolo Boffetta; Charles B Hall; Rachel Zeig-Owens Journal: Am J Ind Med Date: 2021-07-18 Impact factor: 3.079